Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 1.00 |
| ▸ | CA2 | P00918 | 2/20 | 0.58 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.51 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.51 |
| ▸ | CLK1 | P49759 | 8/20 | 0.50 |
| ▸ | DYRK1A | Q13627 | 4/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.45 |
| ▸ | NCF1 | P14598 | 1/20 | 0.44 |
| ▸ | APP | P05067 | 1/20 | 0.43 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.42 |
| ▸ | CLK2 | P49760 | 2/20 | 0.42 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1107212 | 0.85 | BACE1 (0.73) | BACE1CA2PDE3BPDE3ACYP1A2 | |
| SCHEMBL4580171 | 0.80 | BACE1 (0.67) | BACE1CA2PDE3BPDE3ACLK1 | |
| SCHEMBL144533 | 0.78 | BACE1 (0.65) | BACE1CA2PDE3BPDE3ACLK1 | |
| SCHEMBL16023592 | 0.77 | BACE1 (0.62) | BACE1CA2PDE3BPDE3ACLK1 | |
| SCHEMBL5546367 | 0.77 | BACE1 (0.62) | BACE1CA2PDE3BPDE3ACLK1 | |
| SCHEMBL6839989 | 0.77 | BACE1 (0.62) | BACE1CA2PDE3BPDE3ACLK1 | |
| SCHEMBL224122 | 0.77 | BACE1 (0.62) | BACE1CA2PDE3BPDE3ACLK1 | |
| SCHEMBL224116 | 0.76 | BACE1 (0.61) | BACE1CA2PDE3BPDE3ACLK1 | |
| SCHEMBL762071 | 0.74 | BACE1 (0.59) | BACE1CA2PDE3BPDE3ACLK1 | |
| SCHEMBL7340422 | 0.74 | CLK1 (0.67) | BACE1CA2CLK1DYRK1ADYRK1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295101-A1 | THERAPEUTIC COMPOUNDS | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2023-09-21 | — | — | US | disclosed |
| US-11560360-B2 | Therapeutic compounds | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2023-01-24 | — | — | US | disclosed |
| US-20200407333-A1 | THERAPEUTIC COMPOUNDS | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2020-12-31 | — | — | US | disclosed |
| US-10745366-B2 | Therapeutic compounds | ARIZON BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2020-08-18 | — | — | US | disclosed |
| US-20190185441-A1 | THERAPEUTIC COMPOUNDS | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2019-06-20 | — | — | US | disclosed |
| WO-2018039487-A1 | THERAPEUTIC COMPOUNDS | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2018-03-01 | — | — | WO | disclosed |
| US-7973051-B2 | Aminothiazoles as FBPase inhibitors for diabetes | HOFFMAN-LA ROCHE INC. (US) | 2011-07-05 | — | — | US | disclosed |
| EP-2227468-A1 | AMINOTHIAZOLE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2010-09-15 | — | — | EP | disclosed |
| US-20090143448-A1 | NEW AMINOTHIAZOLES AS FBPASE INHIBITORS FOR DIABETES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-04 | — | — | US | disclosed |
| WO-2009068467-A1 | AMINOTHIAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200407333-A1 | THERAPEUTIC COMPOUNDS | CFTR, MC2R, RPS21 | BACE1 671/4885CA2 2546/4885PDE3B 382/4885 |
| US-11560360-B2 | Therapeutic compounds | CFTR, MC2R, RPS21 | BACE1 671/4885CA2 2546/4885PDE3B 382/4885 |
| US-20230295101-A1 | THERAPEUTIC COMPOUNDS | CFTR, C1R, FURIN | BACE1 92/4885CA2 1359/4885PDE3B 988/4885 |
| US-20190185441-A1 | THERAPEUTIC COMPOUNDS | CFTR, C1R, FURIN | BACE1 92/4885CA2 1359/4885PDE3B 988/4885 |
| US-10745366-B2 | Therapeutic compounds | CFTR, C1R, FURIN | BACE1 92/4885CA2 1359/4885PDE3B 988/4885 |
| US-20090143448-A1 | NEW AMINOTHIAZOLES AS FBPASE INHIBITORS FOR DIABETES | FBP1, SLC5A1, DPP4 | BACE1 567/4885CA2 1616/4885PDE3B 1515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.